Compare GGZ & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GGZ | MGNX |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 112.6M |
| IPO Year | N/A | 2013 |
| Metric | GGZ | MGNX |
|---|---|---|
| Price | $15.33 | $1.73 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | 12.8K | ★ 919.7K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 5.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | N/A | ★ $127,626,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.79 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.43 | $0.99 |
| 52 Week High | $12.50 | $3.37 |
| Indicator | GGZ | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 77.84 | 63.44 |
| Support Level | $15.33 | $1.68 |
| Resistance Level | $15.70 | $1.82 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 100.00 | 78.13 |
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.